-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In November 2022, the activity of licensing in and outside of local enterprises and between domestic enterprises recovered
compared with October.
According to GBI
The SOURCE database global trading section, a total of the following 12 related transactions, mainly covering oncology, cardiovascular system, nervous system and other fields
.
Table 1.
November 2022 license to introduce transactions
Table 2.
Licensing transactions in November 2022
Table 3.
Local licensing transaction in November 2022
Source: GBI SOURCE Global Trading Section
GBI SOURCELicensing Introduction Transactions
Licensing Introduction TransactionsLicense-in
Buchang Pharmaceuticals and Remet reached a development and licensing agreement for the REMD-290 related project
Buchang Pharmaceuticals and Remet reached a development and licensing agreement for the REMD-290 related project■ Licensor: Rimet
Licensor:■ Licensee: Buchang Pharmaceutical
Licensee:■ Product/Technology: REMD-290
Product/Technology:Sichuan Luzhou Buchang Biopharmaceutical Co.
, Ltd.
, a subsidiary of Buchang Pharmaceutical, signed a cooperative development and licensing agreement
with Ruimide Biomedical Technology Co.
, Ltd.
of the United States.
Ruimed granted Luzhou Buchang an exclusive license to REMD-290 patent in Chinese mainland and Russia, and Luzhou Buchang selected two bispecific antibody molecules, BC921 and BC922, derivatives of REMD-290 monoclonal antibody, to conduct process research and development, development and commercialization
of the licensed product in the target region.
Luzhou will pay a total of US$14.
2 million in milestone payments, as well as a percentage of the sales commission
.
The parties also agreed in detail on the cost of development, registration and clinical research of the licensed products
.
Simcere Pharmaceuticals received US$50 million authorization from Daridorexant, a new insomnia drug from Idosia in Switzerland
Simcere Pharmaceuticals received US$50 million authorization from Daridorexant, a new insomnia drug from Idosia in Switzerland■ Licensor: Idorsia Pharmaceuticals Ltd
Licensor:■ Licensee: Simcere Pharmaceutical
Licensee:■ Product/Technology: Daridorexant
Product/Technology:Simcere Pharmaceuticals announced a partnership with Swiss biopharmaceutical company Idorsia
Ltd.
enters into an exclusive license agreement
.
Simcere Pharmaceutical has obtained the exclusive rights to develop and commercialize Daridorexant, Idorsia's new anti-insomnia drug, in Greater China (Chinese mainland, Hong Kong and Macau), and will be responsible for the clinical research and development
of the project in China.
Idosia will receive a $30 million down payment and will be eligible for an additional $20 million milestone payment upon approval of the China registration, as well as a low double-digit tiered royalty
based on future sales.
Daridorexant's ability to improve both nighttime sleep and daytime function in adults with chronic insomnia disorder was approved
in the United States and Europe in January and April 2022.
Tenacia acquires exclusive rights in Greater China, a ganaxolone owned by Marinus
Tenacia acquires exclusive rights in Greater China, a ganaxolone owned by Marinus■ Licensor: Marinus Pharmaceuticals, Inc.
■ Licensee: Tenacia Biotechnology
Licensee:■ Product/Technology: Ganaxolone
Product/Technology:U.
S.
pharmaceutical company Marinus Pharmaceuticals Inc.
and Chinese company Tenacia
Biotechnology (Shanghai) Co.
, Ltd.
signed a cooperation and supply agreement
.
Tenacia will acquire exclusive rights
to develop and commercialize the oral and intravenous formulations of ganaxolone by Marinus in Chinese mainland, Hong Kong, Macau and Taiwan.
Tenacia also has the right to prioritize
negotiations for any future next-generation formulation or prodrug.
Marinus will receive $10 million upfront, up to $256 million in administrative, development and sales milestone payments, and low-double-digit tiered royalties
based on future net sales.
Tenacia will be responsible for developing the drug in China for the treatment of CDKL5 deficiency, tuberous sclerosis syndrome and status epilepticus, and will also work with Marinus to develop a new generation of ganaxolone formulations
.
Yuer Pharma acquired the rights to Aclaris' novel JAK1/3 inhibitor, ATI-1777, in Greater China
Yuer Pharma acquired the rights to Aclaris' novel JAK1/3 inhibitor, ATI-1777, in Greater China■ Licensor: Aclaris Therapeutics, Inc.
■ Licensee: Yuer Pharmaceutical
Licensee:■ Product/Technology: ATI-1777
Product/Technology:American company Aclaris Therapeutics,
Inc.
entered into an exclusive license agreement
with Yuer Pharmaceutical.
Yuer Pharma has acquired the rights
to develop, manufacture and commercialize ATI-1777 for all indications, including but not limited to atopic dermatitis, in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan).
Under the agreement, Aclaris will receive an upfront payment of $5 million, up to $91 million in administrative oversight and sales milestone payments, and royalties
based on future sales.
Luca obtains the mainland commercialization rights of Cambridge Cognition's neuropathy assessment tool
Luca obtains the mainland commercialization rights of Cambridge Cognition's neuropathy assessment tool■ Licensor: Cambridge Cognition
Licensor:■ Licensee: Luca Healthcare
Licensee:■ Product/Technology: Not announced
Product/Technology:Luca Healthcare announced that it has partnered with British company Cambridge
Cognition signed a 10-year licensing agreement
.
Under the agreement, Luca will get Cambridge
Cognition's cognitive assessment system is licensed
to commercialize in the Chinese mainland market.
The collaboration includes the CATALAB cognitive testing system, which enables sensitive and objective measures of cognitive function, including working memory, learning, executive function, vision, speech and episodic memory
.
These tests, available in multiple languages and include Chinese, can be used to detect early symptoms
of neurodegenerative diseases such as dementia.
Licensing transactions
Licensing transactionsLicense-out
Sanofi joins hands with Insilico to advance AI pharmaceuticals
Sanofi joins hands with Insilico to advance AI pharmaceuticals■ Licensor: Insilico
Licensor:■ Licensee: Sanofi
Licensee:■ Product/Technology: Pharma.
AI drug discovery platform
Insilico announces a multi-year strategic research collaboration
with Sanofi for multiple targets.
The collaboration will leverage Insilico's artificial intelligence (AI)-driven Pharma.
AI drug discovery platform to advance drug candidate development based on no more than six innovative targets
.
Sanofi will pay Insilico's aggregate upfront payment and target nomination fees of up to US$21.
5 million, supported by Insilico's Pharma.
AI platform and interdisciplinary team of drug discovery scientists to identify, synthesize and advance research on high-quality lead compounds to clinical development
candidates.
If the collaboration reaches key R&D and commercial milestones, Insilico will also receive additional milestone payments, totaling up to $1.
2 billion.
The collaboration will also provide phased royalties
ranging from medium to low double digits for the commercialization of successfully developed products.
AI drug discovery platform
Harbour Biopharma granted Moderna only heavy chain antibody discovery platform and derivative sequence rights for $506 million
Harbour Biopharma granted Moderna only heavy chain antibody discovery platform and derivative sequence rights for $506 million■ Licensor: Harbour Pharmaceutical
Licensor:■ Licensee: Moderna, Inc.
■ Product/Technology: Heavy chain antibody (HCAb) discovery platform only
Product/Technology:Harbour Biopharma announced that its wholly-owned subsidiary, Nona Biologics (Suzhou) Co.
, Ltd.
, has entered into a licensing and partnership agreement
with Moderna.
The collaboration will focus on the discovery and development of nucleic acid-based immunotherapies
using Harbour Biopharma's proprietary heavy-chain antibody (HCAb) discovery platform.
Nona Biologics shall receive an upfront payment of $6 million and potential milestone payments of up to approximately $500 million and will be eligible to collect tiered royalties from Moderna for each product developed under the Agreement
.
In addition, Moderna will be granted an exclusive sublicensable license to develop nucleic acid products
using a set of sequences derived from Harbour Pharma's HCAb platform for multiple targets.
Yifan Pharma granted ACROTECH the right to distribute F-627 in the United States
Yifan Pharma granted ACROTECH the right to distribute F-627 in the United States■ Licensor: Yifan Pharmaceutical
Licensor:■ Licensee: Acrotech Biopharma Inc.
■ Product/Technology: F-627
Product/Technology:Yifan Pharmaceutical issued an announcement that its holding subsidiary Yiyi licensed the exclusive distribution right of the product Ebegastim α injection (formerly known as recombinant human granulocyte colony-stimulating factor-Fc fusion protein, proposed trade name: Yilishu, R&D code: F-627) in the United States to ACROTECH; ACROTECH pays exclusive license fees (including down payment and milestone payments) up to $236.
5 million to the United States, as well as double-digit tiered net sales royalties
.
Biocytogen has entered into an antibody development agreement with ADC Therapeutics
Biocytogen has entered into an antibody development agreement with ADC Therapeutics■ Licensor: Biocytogen
Licensor:■ Licensee: ADC Therapeutics SA
Licensee:■ Product/technology: antibody molecules for 3 tumor targets
Product/Technology:Biocytogen (Beijing) MedTech Co.
, Ltd.
announced a partnership with Switzerland-based ADC Therapeutics
SA signs an optional antibody drug molecule evaluation and authorization agreement
.
Biocytogen licenses ADCs
Therapeutics evaluated
antibody molecules for 3 tumor targets with independent intellectual property rights of Biocytogen.
ADC after completion of evaluation
Therapeutics has the right to license selected antibody molecules for worldwide use in ADC drug development and commercialization; Biocytogen will retain all global benefits
to these antibody molecules for use other than ADC drugs.
Biocytogen will receive an upfront payment and, for each licensed molecule, Biocytogen will receive option execution fees, payment for various stages of development and commercialization milestones, accumulating up to tens of millions of dollars; and single-digit net sales share
.
Local licensing transactions
Local licensing transactionsJichuan Pharmaceutical and Hengyi Biotechnology cooperated to develop two products
Jichuan Pharmaceutical and Hengyi Biotechnology cooperated to develop two products■ Licensor: Hengyi Biotechnology
Licensor:■ Licensee: Jichuan Pharmaceutical
Licensee:■ Products/technologies: PDE4 inhibitors, protease inhibitors
Product/Technology:Jichuan Pharmaceutical Group Co.
, Ltd.
and Hengyi Biopharmaceutical (Shanghai) Co.
, Ltd.
reached an exclusive cooperation agreement to cooperate
in the Chinese mainland (excluding Hong Kong, Macao and Taiwan) for the indications agreed on a PDE4 inhibitor pharmaceutical product (including its various dosage forms) and a combination product (target product 1) and a protease inhibitor pharmaceutical product (including its various dosage forms, target product 2) owned or controlled by Hengyi Biologics 。 The down payment paid by Jichuan Limited will not exceed 180 million RMB, the development milestone payment will not exceed 12.
125 million US dollars, the sales milestone will not exceed 20 million US dollars, and it will share the subsequent R&D expenses of target products 1 and 2 with Hengyi Biotech in the same proportion, and enjoy the sales profit
according to the same proportion.
The existing indications for Target Product 1 are moderate to severe plaque psoriasis and mild to moderate atopic dermatitis, and the existing indication for Target Product 2 is to improve the recovery of intestinal function and reduce postoperative intestinal obstruction
in patients undergoing selective bowel resection.
Hansen Pharmaceutical obtained the rights of Pumis EGFR/cMet dual antibody PM1080 in China
Hansen Pharmaceutical obtained the rights of Pumis EGFR/cMet dual antibody PM1080 in China■ Licensor: Promes Biotechnology
Licensor:■ Licensee: Hansen Pharmaceutical
Licensee:■ Product/Technology: PM1080
Product/Technology:Hansen Pharmaceutical announced that it has obtained an exclusive license
to develop and commercialize Pumis's bispecific antibody PM1080 in China, including Hong Kong, Macau and Taiwan.
Hansen Pharmaceutical will be responsible for the development, registration approval, manufacturing and commercialization of PM1080 in China, and pay a down payment of RMB 50 million, a commercialization milestone payment of up to RMB 1.
418 billion, and a tiered royalty
based on future net sales in China.
PM1080 is an EGFR/cMet bispecific antibody with great therapeutic potential to simultaneously block the signaling of EGFR and c-Met and inhibit tumor growth and survival, and is currently in the preclinical research stage
.
Henlius granted Fosun Pharma Hans-like commercialization rights in the US market
Henlius granted Fosun Pharma Hans-like commercialization rights in the US market■ Licensor: Henlius
Licensor:■ Licensee: Fosun Pharma
Licensee:■ Product/Technology: Serplulimab
Product/Technology:Henlius announced that it has entered into a license agreement with Fosun Pharma Industry, a subsidiary of Fosun Pharma, granting it an exclusive license to
commercialize Hans-like (serplulimab injection) in the US market.
Fosun Pharma is required to make an upfront payment of RMB1 billion to Henlius, a one-off regulatory milestone payment of US$50 million (approximately RMB358 million), a maximum of US$650 million (approximately RMB4.
652 billion) of sales milestone payments, and royalties paid on a pro rata basis based on net sales
.
This transaction aims to enhance the accessibility and recognition of Hans-like in overseas markets through Fosun Pharma's mature system in medical affairs and market access
.
Shanghai Medicine introduced the first generic drug of Ambisen carbamazepine sustained-release tablets, and multi-party cooperation ensured supply and marketing
Shanghai Medicine introduced the first generic drug of Ambisen carbamazepine sustained-release tablets, and multi-party cooperation ensured supply and marketing■ Licensor: Ambisen
Licensor:■ Licensee: Shangyao Zhongxi
Licensee:■ Product/Technology: Carbamazepine
Product/Technology:Shanghai Zhongxi Sanwei Pharmaceutical Co.
, Ltd.
, Shanghai Ambisen Pharmaceutical Technology Co.
, Ltd.
, Qingdao BAHEAL Pharmaceutical Co.
, Ltd.
, and Shanghai Pharmaceutical Group Pharmaceutical Sales Co.
, Ltd.
reached a multi-party cooperation
around the first generic drug of carbamazepine sustained-release tablets (II) under Ambisen.
The generic drug of carbamazepine sustained-release tablets (II) independently developed by Ambisen was first approved by the US FDA in 2021 and sold to the US market; Approved in China in 2022, it is the first imitation in China, and the trade name: Shu Ningping
.
In this cooperation, Ambisen transferred the marketing authorization approval of the three specifications of Shuningping held by Shuningping to Shanghai Pharmaceutical Zhongxi
.
BAHEAL Pharmaceutical will provide Shuningping with stable quality supply guarantee; Shanghai Medicine Sales will be equipped with a professional sales team in the field of Shuningping indications to carry out sales promotion
in the domestic market.